• About us
• Contact

Advertisement

Organisation › Details

Debiopharm International S.A.

Debiopharm Group™ is a Swiss-based global biopharmaceutical group of five companies active in the development and manufacture of drugs and diagnostics tools. Debiopharm focuses on developing prescription drugs that target unmet medical needs. The group in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. *

 

	Start	2015-04-23 existent
	Group	Debiopharm (Group)
	Industry	pharmaceutical
	Industry 2	drug development
	Person	Ducrey, Bertrand (Debiopharm 201610 CEO of Debiopharm International)
	Region	Lausanne VD
	Country	Switzerland
	Street	5–7 Chemin Messidor Forum »après-demain«
	City	1002 Lausanne VD
	Tel	+41-21-321-0111
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-06-26

Advertisement

More documents for Debiopharm (Group)

• [1] Merck KGaA. (6/24/24). "Press Release: Merck Provides Update on Xevinapant Program in Locally Advanced Head and Neck Cancer [ Not intended for UK-, US- or Canada-based media ]". Darmstadt....
• [2] Merck KGaA. (3/1/21). "Press Release: Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant". Darmstadt....
• [3] Voluntis S.A.. (11/23/20). "Press Release: Voluntis Successfully Completes a Capital Increase of €5.9 Million and Finalizes the Financing of Its Strategic Roadmap [Not for US, CA, AU or JP] Japan.". Cambridge, MA & Paris....
• [4] Debiopharm International SA. (9/7/20). "Press Release: Belgian Scale-up Oncomfort Raises €10 million in Series A Funding Co-led by Debiopharm and Crédit Mutuel Innovation". Brussels, Lausanne & Paris....
• [5] Debiopharm International SA. (7/7/20). "Press Release: Nucleai Secured $6.5m Series-A Initial Closing Led by Debiopharm to Advance Ai-Powered Precision Oncology Platform". Tel Aviv & Lausanne....
• [6] Debiopharm International SA. (3/25/20). "Press Release: Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-licensing Agreement of 3B Pharmaceutical’s Targeted CAIX Radiotherapy". Lausanne....
• [7] Novadiscovery SAS. (1/9/20). "Press Release: Novadiscovery Raises Series A Financing to Scale Its in silico Clinical Trial Platform – Debiopharm Leads the Round with EUR 5 Million"....
• [8] Debiopharm International SA. (6/12/19). "Press Release: Debiopharm and Ipsen Extend Their Strategic Decapeptyl (triptorelin) Partnership for another 15 Years". Lausanne & Paris....
• [9] Debiopharm International SA. (5/14/19). "Press Release: Debiopharm Awarded $2.1 Million from CARB-X in the Fight against a Highly Resistant Nosocomial-pneumonia Causing Superbug". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.